公开(公告)号：US12139538B2

公开(公告)日：2024-11-12

申请号：US17332853

申请日：2021-05-27

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

Inventor： Renier J. Brentjens ,  Eric L. Smith ,  Cheng Liu

IPC: C07K16/00 ,  A61K35/17 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/12 ,  C12N15/86

Abstract: The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.

公开(公告)号：US11993661B2

公开(公告)日：2024-05-28

申请号：US17253589

申请日：2019-06-17

Applicant: EUREKA THERAPEUTICS, INC.

Inventor： Hong Liu ,  Hongruo Yun ,  Xiaomei Ge ,  Zhiyuan Yang ,  Lianxing Liu ,  Pengbo Zhang ,  Yixiang Xu ,  Shan Li ,  Lucas Horan

IPC: C07K16/00 ,  A61P35/00 ,  C07H21/04 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C12N5/02 ,  C12N15/00 ,  G01N33/574

CPC classification number: C07K16/3069 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2809 ,  G01N33/57434 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

Abstract: The present application provides constructs comprising an antibody moiety that specifically binds to PSMA (e.g., PSMA expressed on the surface of a cell). Also provided are methods of making and using these constructs.

公开(公告)号：US11827672B2

公开(公告)日：2023-11-28

申请号：US17043352

申请日：2019-03-29

Applicant: Eureka Therapeutics, Inc.

Inventor： Jun Cui ,  Pengbo Zhang ,  Yiyang Xu ,  Shan Li ,  Yixiang Xu ,  Guangyan Xiong ,  Hongruo Yun ,  Lianxing Liu ,  Xiaomei Ge ,  Shaohua Xu ,  Hong Liu ,  Javier Morales

IPC: C07K16/28 ,  A61P35/00 ,  C07K14/725 ,  A61K39/00 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/2809 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  G01N2333/70503

Abstract: Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.

公开(公告)号：US20230048360A1

公开(公告)日：2023-02-16

申请号：US17817308

申请日：2022-08-03

Applicant: Eureka Therapeutics, Inc.

Inventor： Pengbo ZHANG ,  Yiyang Xu ,  Javier Morales ,  Yoko Nakano ,  Hong Liu ,  Jingyi Xiang ,  Timothy Acker

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  G01N33/574

Abstract: The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.

公开(公告)号：US11566071B2

公开(公告)日：2023-01-31

申请号：US16732022

申请日：2019-12-31

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

Inventor： Renier J. Brentjens ,  Eric L. Smith ,  Cheng Liu

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  G01N33/68

Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.

公开(公告)号：US20230020729A1

公开(公告)日：2023-01-19

申请号：US17332853

申请日：2021-05-27

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

Inventor： Renier J. Brentjens ,  Eric L. Smith ,  Cheng Liu

IPC: C07K16/28 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N9/12 ,  A61K39/00 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/86

Abstract: The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.

公开(公告)号：US20220348629A1

公开(公告)日：2022-11-03

申请号：US17716667

申请日：2022-04-08

Applicant: EUREKA THERAPEUTICS, INC.

Inventor： Jingwei LU ,  Zhiyuan YANG ,  Cheng LIU ,  Hong LIU ,  Yiyang XU ,  Su YAN ,  Vivien Wai-Fan CHAN ,  Lucas HORAN

IPC: C07K14/725 ,  A61K35/17 ,  C12N15/62 ,  A61K38/00 ,  A61P35/00 ,  A61K39/395 ,  C07K16/28

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

公开(公告)号：US20220323497A1

公开(公告)日：2022-10-13

申请号：US17628120

申请日：2020-07-24

Applicant: Eureka Therapeutics, Inc.

Inventor： Hongruo YUN ,  Jun Cui ,  Pengbo Zhang ,  Yiyang Xu ,  Lucas Horan ,  Shaohua Xu ,  Guangyan Xiong ,  Shan Li ,  Yixiang Xu ,  Bradley Austin Heller ,  Hongbing Zhang ,  Hong Liu

IPC: A61K35/17 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  A61P35/00

Abstract: Described herein are immune cells comprising: a chimeric antigen receptor (CAR) that comprises (i) an extracellular target-binding domain comprising an antibody moiety; (ii) a transmembrane domain; and (iii) a primary signaling domain, and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain. Also provided herein are methods of using the same or compositions thereof for therapeutic treatment of cancers (e.g., hematological cancers or solid tumor cancers).

公开(公告)号：US11447564B2

公开(公告)日：2022-09-20

申请号：US16608377

申请日：2018-04-24

Applicant: EUREKA THERAPEUTICS, INC.

Inventor： Pengbo Zhang ,  Yiyang Xu ,  Javier Morales ,  Yoko Nakano ,  Hong Liu ,  Jingyi Xiang ,  Timothy Acker

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  G01N33/574 ,  A61K39/00

Abstract: The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.

公开(公告)号：US20220235143A1

公开(公告)日：2022-07-28

申请号：US17609053

申请日：2020-05-07

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

Inventor： David SPRIGGS ,  Dharmarao THAPI ,  Su YAN ,  Cheng LIU

IPC: C07K16/30 ,  A61K47/68 ,  A61P35/00 ,  C12N5/0783 ,  A61K35/17 ,  A61K39/395 ,  G01N33/574 ,  A61K51/10 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  A61K38/17 ,  A61P35/04

Abstract: Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.